Drug Trial Radar · NCT06155487
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Dec 5, 2023
Primary completion
Apr 28, 2026
Study completion Apr 28, 2026
Sponsor
- Lead sponsor
- JMackem Co., LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Seoul National University Hospital
- First posted
- Dec 4, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this randomized, double-blind, placebo-controlled Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of AJH-2947 in healthy Korean or Caucasian adult male participants.
Conditions
- Healthy Volunteers
- Chronic Pain Syndrome
Interventions
AJH-2947 tablets or placeboDrug
Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A (SAD): Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 7
- Part A (SAD): Area under the concentration-time curve to the last quantifiable concentration (AUClast)Time frame: Day 1 to Day 7
- Part A (SAD): Area under the concentration-time curve extrapolated to infinity (AUCinf)Time frame: Day 1 to Day 7
- Part B (MAD): Maximum observed plasma concentration following the first dose (Cmax)Time frame: Day 1 to Day 2
- Part B (MAD): Area under the concentration-time curve over the dosing interval following the first dose (AUCtau)Time frame: Day 1 to Day 2
- Part B (MAD): Maximum observed plasma concentration at steady state (Cmax,ss)Time frame: Day 7 to Day 8
- Part B (MAD): Area under the concentration-time curve over the dosing interval at steady state (AUCtau,ss)Time frame: Day 7 to Day 8
- Number of participants with AEs, SAEs, and clinically significant safety findingsTime frame: From signing informed consent through the post-study visit (up to Day 18)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.